A deal with the Trump administration to pay more for new medicines will cost the health service in England an initial £1bn over the first three years, the government has acknowledged.
Lord Patrick Vallance, the science minister, confirmed that the Department of Health and Social Care would fund the extra spending out of its existing budget, prompting questions about whether the deal was value for money.
Costs are likely to increase further beyond the current spending review period as Vallance said that the UK government was “committed to accelerating spend on innovative medicines over the next 10 years”.
您已阅读17%（609字），剩余83%（2891字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。